We are a non-profit organization making huge strides in research and medical advancements for pediatric brain cancer.
What We Do
Every donation is making huge strides in research and medical advancements for pediatric brain cancer. In fact, we have a letter from Peter C. Phillips, M.D, Chief, Division of Neuro-Oncology from The Children’s Hospital of Philadelphia on the progress of the Fundraising from Wylie’s Day:
January 29, 2013
Dear Steph and John:
During the past year we have used the funding support from Wylie’s Day and Strotbeck Foundation sources entirely for the Childhood Brain Tumor Tissue Consortium effort at CHOP. To that objective we have now entered more than three hundred and fifty brain tumor samples together with comprehensive clinical data relating to the surgical treatment, radiation or chemotherapy treatment, and response for these children. As you know, we have developed a sophisticated series of procedures to separate all clinical identifiers for the tissue samples and the clinical information. Accordingly, we are able to maintain a high level of confidentiality while preserving an extensive body of clinical data that can be used to address complex therapeutic questions.
Currently, we have more than 100 low-grade astrocytomas, more than 70 medulloblastomas, and more than 75 malignant gliomas in addition to more than 20 other types of tumors that are stored in our repository. As you may remember, we have no restrictions on tissue types, so we also collect some of the most uncommon tumors with the plan of assessing their genomic characteristics in the future.The CBTTC efforts are centered at CHOP because we have the most comprehensive infrastructure for tumor storage, neuropathological assessment, and automated gene-chip analysis. In addition, we have established a partnership with the Beijing Genomics Institute (BGI), one of the world leaders in rapid gene sequencing and analysis. This will reduce the cost of tissue genetic analysis and greatly facilitate the speed at which we can undertake new research projects. The CBTTC will have full access to these resources and it will facilitate our selected efforts at complete gene sequencing of certain tumor types. Our collaborators in the CBTTC include the University of Pittsburgh, Chicago Memorial Hospital, and University of Washington in Seattle. We will be meeting in March 2013 to establish data analysis schedules and priorities, to review the current data, and to explore opportunities to expand the CBTTC to other participants. As a group, we have initiated a research project on childhood astrocytomas, partially funded by the CBTTC including your support, partially funded by the Low Grade Astrocytoma Foundation and are in the process of gene sequencing for that study. We anticipate early results this winter.
As always, we are deeply appreciative of your support for this uniquely important collaboration between major institutions and we anticipate that our efforts will continue to stimulate new therapeutic strategies and identify new therapeutic targets based on the gene structure and mutation patterns of these tumors. I look forward to seeing you at the event on Saturday night.
Best regards,
Peter C. Phillips, M.D.
Chief, Division of Neuro-Oncology
January 29, 2013
Dear Steph and John:
During the past year we have used the funding support from Wylie’s Day and Strotbeck Foundation sources entirely for the Childhood Brain Tumor Tissue Consortium effort at CHOP. To that objective we have now entered more than three hundred and fifty brain tumor samples together with comprehensive clinical data relating to the surgical treatment, radiation or chemotherapy treatment, and response for these children. As you know, we have developed a sophisticated series of procedures to separate all clinical identifiers for the tissue samples and the clinical information. Accordingly, we are able to maintain a high level of confidentiality while preserving an extensive body of clinical data that can be used to address complex therapeutic questions.
Currently, we have more than 100 low-grade astrocytomas, more than 70 medulloblastomas, and more than 75 malignant gliomas in addition to more than 20 other types of tumors that are stored in our repository. As you may remember, we have no restrictions on tissue types, so we also collect some of the most uncommon tumors with the plan of assessing their genomic characteristics in the future.The CBTTC efforts are centered at CHOP because we have the most comprehensive infrastructure for tumor storage, neuropathological assessment, and automated gene-chip analysis. In addition, we have established a partnership with the Beijing Genomics Institute (BGI), one of the world leaders in rapid gene sequencing and analysis. This will reduce the cost of tissue genetic analysis and greatly facilitate the speed at which we can undertake new research projects. The CBTTC will have full access to these resources and it will facilitate our selected efforts at complete gene sequencing of certain tumor types. Our collaborators in the CBTTC include the University of Pittsburgh, Chicago Memorial Hospital, and University of Washington in Seattle. We will be meeting in March 2013 to establish data analysis schedules and priorities, to review the current data, and to explore opportunities to expand the CBTTC to other participants. As a group, we have initiated a research project on childhood astrocytomas, partially funded by the CBTTC including your support, partially funded by the Low Grade Astrocytoma Foundation and are in the process of gene sequencing for that study. We anticipate early results this winter.
As always, we are deeply appreciative of your support for this uniquely important collaboration between major institutions and we anticipate that our efforts will continue to stimulate new therapeutic strategies and identify new therapeutic targets based on the gene structure and mutation patterns of these tumors. I look forward to seeing you at the event on Saturday night.
Best regards,
Peter C. Phillips, M.D.
Chief, Division of Neuro-Oncology
How funding from the Wylie's Day Foundation is helping?
The Children's Brain Tumor Tissue Consortium requires a financial commitment. The CBTTC is completely funded by donor support. Without donors, the work of the CBTTC would not be possible.
The Children's Brain Tumor Tissue Consortium requires a financial commitment. The CBTTC is completely funded by donor support. Without donors, the work of the CBTTC would not be possible.